Navigation Links
Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009
Date:11/16/2009

BEDFORD, Mass., Nov. 16 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, is participating in the 38(th) Annual American Association of Gynecologic Laparoscopists (AAGL) conference, November 15-19, 2009 in Orlando, Florida, and will feature its Adiana(®) permanent contraception system.

Adiana is a minimally invasive procedure that requires no incisions and can be performed in the comfort of the doctor's office using local anesthesia. The Adiana system is designed to provide women a minimally invasive alternative to traditional, surgical means of permanent contraception. With the Adiana system, patients are normally able to return to work or resume their daily activities within one day. In contrast, traditional methods of permanent contraception, such as tubal ligation, require more invasive surgical procedures, usually are conducted in a hospital under general anesthesia, and typically require four to five days of recovery.

"AAGL is the most influential meeting for physicians providing patient care through minimally invasive gynecology," said Tony Kingsley, senior vice president, GYN surgical products at Hologic. "As we have learned through numerous patient testimonials, women are undergoing the Adiana procedure to seek relief from the uncertainty and hassle of temporary birth control methods. At Hologic, we continue to bring to market tools that allow physicians to offer women in-office alternatives for their long-term contraception and other gynecological needs."

At AAGL, physicians will present open communication sessions and poster presentations on the Adiana system and the hysteroscopic sterilization method used during the Adiana procedure. Primary investigators will present new data from studies on the Adiana system.

Approved by the Food and Drug Administration (FDA) in July 2009, the Adiana procedure is indicated for women who desire permanent birth control by occlusion of the fallopian tubes.

Ideal candidates include women who do not want children in the future and would like the peace of mind and convenience of permanent birth control.

Sessions for information and key findings about Adiana at AAGL include:

  • "Adiana System for Transcervical Sterilization: 3-Year Efficacy Results;" presented by T.L. Anderson, T.G. Vancaillie; Open Communications; 6 -- Hysteroscopy (Wednesday, 11/18 at 11:48 pm)
  • "Mechanism of Action of the Adiana Device: A Histologic Perspective;" presented by T.G. Vancaillie, D. Harrington, V. Carr-Brendel, J. Anderson; Open Communications; 14 -- Hysteroscopy (Wednesday, 11/18 at 3:44 pm)
  • "Evaluating the Learning Curve for a Novel Hysteroscopic Sterilization Technique;" presented by M.Y. Bongers, S. Veersema; Open Communications; 16 -- Hysteroscopy (Thursday, 11/19 at 8:12 am)
  • "Feasibility of Hysterosalpingography To Evaluate Tubal Occlusion Following Concomitant Adiana(®) Transcervical Sterilization and NovaSure(®) Endometrial Ablation;" presented by J. Garza-Leal, I. Hernandez, L. Castillo, R. Livengood, M. Stillman, J.E. Coad; Poster Presentation
  • "Concominant Use of Adiana(®) Permanent Contraception and NovaSure(®) Impedance Controlled Endometrial Ablation: A Peri-Hysterectomy Study;" presented by J. Garza-Leal, I. Hernandez, L. Castillo, R. Livengood, M. Stillman, J.E. Coad; Open Communications; 14 -- Hysteroscopy (Wednesday, 11/18 at 3:26 pm)

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.

Forward-Looking Statement Disclaimer

This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of the Adiana permanent contraception system. There can be no assurance the system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the Adiana permanent contraception system can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.

Hologic, Adiana and NovaSure are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

    Contact:  Stephanie Cilibrasi                          Anne Rivers
              Product Manager, Adiana Product Marketing    Corporate Marketing
              Hologic, Inc.                                Hologic, Inc.
              (339) 221-3292                               (508) 263-8765
              Email: adianamedia@hologic.com

SOURCE Hologic, Inc.


'/>"/>
SOURCE Hologic, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...  This month,s issue of the Journal of ... in-depth look at various causes and consequences associated with rising health ... which has generated significant public outrage and calls for ... E. Happe , PharmD, MPH. --> JMCP ... --> In 2014 prescription drug spending in ...
(Date:2/12/2016)... Pharmacy, Inc. (NYSE: DPLO ) is pleased to announce the promotion of Paul ... Jan. 23, 2016. To learn more about ... ... ... In his ...
(Date:2/12/2016)... 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in ... Okaloosa County Emergency Medical Services (EMS) consisting ... one LT2 van. Quality Emergency Vehicles in Lecanto, ... the sale.  This is the latest in Demers, ongoing expansion ... President at Demers. --> Benoit LaFortune , Executive ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... (INS) states that vein visualization technology should be used to ensure patient safety ... the world, the INS Standards mandate the use of vein visualization technology in ...
(Date:2/13/2016)... , ... February 13, 2016 , ... When an Au Pair comes all ... sure what they are in for and they are often worried things won’t go well. ... were hoping for. This year’s Au Pair of the Year winner’s all commented how their ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi , a ... Providers list for its expertise in eClinical Solutions. DDi has built its solution ... technology needs of global clients. DDi provides smarter technology for Clinical Development, Regulatory ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s Day tips ... biography of Rama - Dr. Frederick Lenz. , According to Publisher Roger ... Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love in all ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
Breaking Medicine News(10 mins):